Durable response of anaplastic thyroid cancer to pembrolizumab combined with chemotherapy: A case report.

Hum Vaccin ImmunotherApr 16, 2026 (epub)
Case ReportOncology (Medical)Open access

Zipei Chen, Qiongshan Chen, Yihan Zhuang et al.

✦ AI-curated · Sources linked

Case in brief

A patient with anaplastic thyroid cancer, characterized as BRAF V600E wild-type and PD-L1-positive, presented with residual disease after surgery and progression on multi-targeted therapy. Treatment with pembrolizumab, nab-paclitaxel, and carboplatin led to a near-complete response that lasted over 30 months, demonstrating a manageable safety profile.

Diagnostic / clinical pearl

Clinicians should consider the potential of combining pembrolizumab with chemotherapy in treating anaplastic thyroid cancer, especially in cases lacking actionable mutations.

Why it matters

This case highlights the need for further research into combination therapies for anaplastic thyroid cancer, which may improve outcomes in this aggressive malignancy.

Source

PubMed · PMID 41988746Free full text on PubMed Central

Published in Hum Vaccin Immunother. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchVascular SurgeryOpen access

Revascularization of Asymptomatic Carotid Artery Stenosis: Cognitive Results of the CREST-2 Randomized Trials.

This prespecified cognitive-outcomes analysis of the multicentre, randomised CREST-2 trials assessed patients aged 35 years or older with at least 70% asymptomatic carotid stenosis.

JAMAOct 27, 2026Read summary
Clinical ResearchObstetrics & GynecologyOpen access

Intrauterine Mepivacaine Instillation vs Placebo for Pain During IUD Placement: A Randomized Clinical Trial.

This multicentre, double-blind, randomised, placebo-controlled trial tested intrauterine mepivacaine before IUD placement in nulliparous individuals aged 18 to 31 years at 11 Swedish clinics.

JAMAOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.